Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2010 Feb;16(2):248-51. doi: 10.1177/1352458509355462. Epub 2009 Dec 22.

A randomized trial of memantine as treatment for spasticity in multiple sclerosis.

Author information

1
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. LRMehta@evergreenhealthcare.org

Abstract

We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks. Eligible MS patients had to have an Ashworth spasticity rating of 2 or higher in at least one lower extremity muscle group. Subjects were randomized to receive either placebo or memantine 10 mg twice a day. The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00638027.

PMID:
20028712
DOI:
10.1177/1352458509355462
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center